Immunocytokines: A novel class of products for the treatment of chronic inflammation and autoimmune conditions

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 180-189

  Bootz, Franziska ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALDESLEUKIN; BETA1A INTERFERON; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; DACLIZUMAB; DARLEUKIN; DEKAVIL; FILGRASTIM; GAMMA1B INTERFERON; GOLIMUMAB; IMMUNOCYTOKINE; INFLIXIMAB; INTERFERON BETA SERINE; OPRELVEKIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; RECOMBINANT ALPHA2B INTERFERON; SARGRAMOSTIM; SECUKINUMAB; SILTUXIMAB; TASONERMIN; TETRAVIL; TOCILIZUMAB; USTEKINUMAB; MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; AUTOIMMUNE DISEASE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHRONIC INFLAMMATION; CIRCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG ELIMINATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENDOMETRIOSIS; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTERNALIZATION; MACROPHAGE; MEAN RESIDENCE TIME; MONOCYTE; NEUTROPHIL; NONHUMAN; PRODUCT DEVELOPMENT; PROTEIN EXPRESSION; PSORIASIS; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; AUTOIMMUNE DISEASES; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; INFLAMMATION;

EID: 84960272911     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.10.012     Document Type: Review

References (136)

1. I. Roifman, and et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review Can. J. Cardiol. 27 2011 174 182
2. E. Shacter, and S.A. Weitzman Chronic inflammation and cancer Oncology 16 2002 217 226 229; discussion 230-212
3. K. Murphy, and et al. Janeway's Immunobiology 8th edn 2012 Garland Science
4. G. Walsh Biopharmaceutical benchmarneri@pharma.ethz.chneri@pharma.ethz.chks 2014 Nat. Biotechnol. 32 2014 992 1000
5. M.C. Genovese, and et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum. 50 2004 1412 1419
6. S.R. Schmidt Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges 2013 Wiley
7. C. Hess, and et al. Emerging classes of armed antibody therapeutics against cancer MedChemComm 5 2014 408 431
8. N. Pasche, and D. Neri Immunocytokines: a novel class of potent armed antibodies Drug Discov. Today 17 2012 583 590
9. K. Asadullah, and et al. Interleukin-10 therapy - review of a new approach Pharmacol. Rev. 55 2003 241 269
10. D.M. Kurtz, and et al. Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51 Leuk. Lymphoma 48 2007 1290 1298
11. R.P. Whitehead, and et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study J. Immunother. 25 2002 352 358
12. R.P. Whitehead, and et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study J. Immunother. 21 1998 440 446
13. P.H. Wiernik, and et al. Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92) J. Immunother. 33 2010 1006 1009
14. K. Ghoreschi, and et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease Nat. Med. 9 2003 40 46
15. M.L. Roberti, and et al. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris J. Biol. Regul. Homeost. Agents 28 2014 133 139
16. A.C. Horsfall, and et al. Suppression of collagen-induced arthritis by continuous administration of IL-4 J. Immunol. 159 1997 5687 5696
17. S.H. Ho, and et al. Protection against collagen-induced arthritis by electrotransfer of an expression plasmid for the interleukin-4 Biochem. Biophys. Res. Commun. 321 2004 759 766
18. L.A. Joosten, and et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis Arthritis Res. 1 1999 81 91
19. W.A. Border, and N.A. Noble Targeting TGF-beta for treatment of disease Nat. Med. 1 1995 1000 1001
20. N.M. Kumar, and et al. Induction of interleukin-1 and interleukin-8 mRNAs and proteins by TGF beta 1 in rat lung alveolar epithelial cells J. Cell. Physiol. 169 1996 186 199
21. L.F. Fajardo, and et al. Dual role of tumor necrosis factor-alpha in angiogenesis Am. J. Pathol. 140 1992 539 544
22. T. Kasama, and et al. Biphasic regulation of the development of murine type II collagen-induced arthritis by interleukin-12: possible involvement of endogenous interleukin-10 and tumor necrosis factor alpha Arthritis Rheum. 42 1999 100 109
23. S. Mocellin, and et al. Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol. 78 2005 1043 1051
24. J.E. Thaxton, and S. Sharma Interleukin-10: a multi-faceted agent of pregnancy Am. J. Reprod. Immunol. 63 2010 482 491
25. T. Biedermann, and M. Rocken Pro- and anti-inflammatory effects of IL-4: from studies in mice to therapy of autoimmune diseases in humans Ernst Schering Res. Found. Workshop 50 2005 235 242
26. J. Scheller, and et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6 Biochim. Biophys. Acta 1813 2011 878 888
27. J.M. Cavaillon Pro- versus anti-inflammatory cytokines: myth or reality Cell. Mol. Biol. 47 2001 695 702
28. J.B. Spangler, and et al. Insights into cytokine-receptor interactions from cytokine engineering Annu. Rev. Immunol. 33 2015 139 167
29. E.S. Ward, and et al. Targeting FcRn for the modulation of antibody dynamics Mol. Immunol. 67 2015 131 141
30. D.M. King, and et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients J. Clin. Oncol. 22 2004 4463 4473
31. A. Ribas, and et al. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma J. Transl. Med. 7 2009 68
32. A. Tzeng, and et al. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution Proc. Natl. Acad. Sci. U. S. A. 112 2015 3320 3325
33. L. Borsi, and et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int. J. Cancer 102 2002 75 85
34. G.P. Adams, and et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers Clin. Cancer Res. 12 2006 1599 1605
35. A.M. Wu, and et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers Immunotechnology 2 1996 21 36
36. J.S. Huston, and et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 85 1988 5879 5883
37. P. Holliger, and et al. "Diabodies": small bivalent and bispecific antibody fragments Proc. Natl. Acad. Sci. U. S. A. 90 1993 6444 6448
38. L. Borsi, and et al. Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 2003 4384 4392
39. C. Hess, and D. Neri Tumor-targeting properties of novel immunocytokines based on murine IL1beta and IL6 Protein Eng. Des. Sel. 27 2014 207 213
40. V. Gafner, and et al. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties Int. J. Cancer 119 2006 2205 2212
41. C. Halin, and et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature Nat. Biotechnol. 20 2002 264 269
42. N. Pasche, and et al. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel Clin. Cancer Res. 18 2012 4092 4103
43. R. Sommavilla, and et al. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12 Protein Eng. Des. Sel. 23 2010 653 661
44. S.D. Gillies A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity Protein Eng. Des. Sel. 26 2013 561 569
45. B. Borgia, and et al. A proteomic approach for the identification of vascular markers of liver metastasis Cancer Res. 70 2010 309 318
46. J.N. Rybak, and et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases Cancer Res. 67 2007 10948 10957
47. V. Strassberger, and et al. Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer J. Proteomics 73 2010 1954 1973
48. D. Hristodorov, and et al. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases Toxins 4 2012 676 694
49. S.Y. Terry, and et al. In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages Eur. J. Nucl. Med. Mol. Imaging 42 2015 1430 1438
50. J. Hamann, and et al. EMR1, the human homolog of F4/80, is an eosinophil-specific receptor Eur. J. Immunol. 37 2007 2797 2802
51. F. Legrand, and et al. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders J. Allergy Clin. Immunol. 133 2014 1439 1447
52. C. Hughes, and et al. Human single-chain variable fragment that specifically targets arthritic cartilage Arthritis Rheum. 62 2010 1007 1016
53. P. Laverman, and et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis J. Nucl. Med. 56 2015 778 783
54. E. Fischer, and et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies Clin. Cancer Res. 18 2012 6208 6218
55. D. Neri, and C.T. Supuran Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discov. 10 2011 767 777
56. D. Neri, and R. Bicknell Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446
57. F. Bootz, and et al. Alternatively spliced EDA domain of fibronectin is a target for pharmacodelivery applications in inflammatory bowel disease Inflamm. Bowel Dis. 21 2015 1908 1917
58. K.L. Gutbrodt, and et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia Sci. Transl. Med. 5 2013 201ra118
59. T. Hemmerle, and et al. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation J. Dermatol. Sci. 76 2014 96 103
60. M. Pedretti, and et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies Atherosclerosis 208 2010 382 389
61. K. Schwager, and et al. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model Hum. Reprod. 26 2011 2344 2352
62. K. Schwager, and et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis Arthritis Res. Ther. 11 2009 R142
63. E. Trachsel, and et al. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo J. Invest. Dermatol. 127 2007 881 886
64. A. Villa, and et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int. J. Cancer 122 2008 2405 2413
65. E. Trachsel, and et al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis Arthritis Res. Ther. 9 2007 R9
66. F. Doll, and et al. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse Arthritis Res. Ther. 15 2013 R138
67. T. Hemmerle Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis Proc. Natl. Acad. Sci. U. S. A. 111 2014 12008 12012
68. Duerner, L.J., et al. (2014) Roche Glycart Ag. Interleukin-10 Fusion Proteins and Uses Thereof. WO2014023673 A1
69. C. Hughes, and et al. Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency Arthritis Res. Ther. 16 2014 R151
70. F. Quattrone, and et al. The targeted delivery of interleukin 4 inhibits development of endometriotic lesions in a mouse model Reprod. Sci. 22 2015 1143 1152
71. S.E. Wythe, and et al. Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide Ann. Rheum. Dis. 72 2013 129 135
72. S. Brandenburg, and et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells Eur. J. Immunol. 38 2008 1643 1653
73. T. Dietrich, and et al. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells Atherosclerosis 220 2012 329 336
74. S. Gillessen, and et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist Eur. J. Immunol. 25 1995 200 206
75. M.K. Gately, and et al. Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo Ann. N. Y. Acad. Sci. 795 1996 1 12
76. O. Shimozato, and et al. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects Immunology 117 2006 22 28
77. T. Hemmerle, and D. Neri The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer Int. J. Cancer 134 2014 467 477
78. K. Frey, and et al. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation Integr. Biol. 3 2011 468 478
79. T. Hemmerle, and D. Neri The dose-dependent tumor targeting of antibody-IFNgamma fusion proteins reveals an unexpected receptor-trapping mechanism in vivo Cancer Immunol. Res. 2 2014 559 567
80. C. Ebbinghaus, and et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy Int. J. Cancer 116 2005 304 313
81. C. Halin, and et al. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins Int. J. Cancer 102 2002 109 116
82. S. Melkko, and et al. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance Int. J. Radiat. Oncol. Biol. Phys. 54 2002 1485 1490
83. U. Niesner, and et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides Bioconjug. Chem. 13 2002 729 736
84. C. Halin, and et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res. 63 2003 3202 3210
85. T. Hemmerle, and et al. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data Protein Eng. Des. Sel. 25 2012 851 854
86. D. Venetz, and et al. Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies Proc. Natl. Acad. Sci. U. S. A. 112 2015 2000 2005
87. M. Galeazzi, and et al. A Phase IB clinical trial in rheumatoid arthritis of DEKAVIL (F8-IL10), a novel anti-inflammatory immunocytokine Ann. Rheum. Dis. 73 Suppl. 2 2014 675 676
88. M. Galeazzi, and et al. DEKAVIL (F8-IL10), a novel therapeutic approach for rheumatoid arthritis: ongoing phase Ib clinical trial results Ann. Rheum. Dis. 74 Suppl. 2 2015 726
89. E. Balza, and et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha Int. J. Cancer 127 2010 101 110
90. S.D. Gillies, and et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer Cancer Immunol. Immunother. 51 2002 449 460
91. C. Hess, and D. Neri The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity Cancer Immunol. Immunother. 64 2015 635 644
92. D.A. Heuveling, and et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients J. Nucl. Med. 54 2013 397 401
93. S.A. Hilderbrand, and R. Weissleder Near-infrared fluorescence: application to in vivo molecular imaging Curr. Opin. Chem. Biol. 14 2010 71 79
94. S.G. Werner, and et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology Ann. Rheum. Dis. 71 2012 504 510
95. R. Bissonnette, and et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept J. Am. Acad. Dermatol. 63 2010 228 234
96. F.C. Breedveld, and et al. The PREMIER study - a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum. 54 2006 26 37
97. K.A. Papadakis Adalimumab for the treatment of Crohn's disease Expert Rev. Clin. Immunol. 2 2006 11 15
98. D. van der Heijde, and et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 54 2006 2136 2146
99. S. Danese Adalimumab for ulcerative colitis: a little is better than none? Inflamm. Bowel Dis. 18 2012 793 794
100. R. Burgos-Vargas Juvenile onset spondyloarthropathies: therapeutic aspects Ann. Rheum. Dis. 61 2002 iii33 iii39
101. J.J. Chan, and K. Gebauer Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab) Australas. J. Dermatol. 44 2003 116 120
102. R.N. Maini, and et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552 1563
103. S. Rossetti, and et al. The use of the anti-tumour necrosis factor monoclonal antibody-infliximab-to treat ulcerative colitis: implications and trends beyond the available data Dig. Liver Dis. 36 2004 426 431
104. H.M. van Dullemen, and et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
105. M.S. Chimenti, and et al. Profile of certolizumab and its potential in the treatment of psoriatic arthritis Drug Des. Dev. Ther. 7 2013 339 348
106. E. Keystone, and et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum. 58 2008 3319 3329
107. R. Landewe, and et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study Ann. Rheum. Dis. 73 2014 39 47
108. P. Rutgeerts, and et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease Int. J. Colorectal Dis. 23 2008 289 296
109. V. Oldfield, and G.L. Plosker Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis BioDrugs 23 2009 125 135
110. W.J. Sandborn, and et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 85 95
111. I. Kone-Paut, and et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study Arthritis Res. Ther. 13 2011 R202
112. N. Schlesinger, and et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions Ann. Rheum. Dis. 71 2012 1839 1848
113. F. Vincenti, and et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N. Engl. J. Med. 338 1998 161 165
114. C.L. Leonardi, and et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
115. P.C. Gisondi, and et al. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy Dermatol. Ther. 4 2014 1 9
116. Y. Okuda Review of tocilizumab in the treatment of rheumatoid arthritis Biologics 2 2008 75 82
117. F. van Rhee, and et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial Lancet Oncol. 15 2014 966 974
118. M.B. Atkins, and et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J. Clin. Oncol. 17 1999 2105 2116
119. W.H. West, and et al. Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma Mol. Biother. 1 1989 268 274
120. C. Isaacs, and et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin J. Clin. Oncol. 15 1997 3368 3377
121. R. Baumgarten, and et al. Treatment of chronic hepatitis B with interferon alpha-2b Gastroenterol. J. 50 1990 124 128
122. P. von Wussow, and et al. Intralesional interferon-alpha therapy in advanced malignant melanoma Cancer 61 1988 1071 1074
123. H.M. Golomb, and et al. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia Semin. Oncol. 14 1987 13 17
124. P.S. Gill Phase I/Ii trials of alpha-interferon alone or in combination with zidovudine as maintenance therapy following induction chemotherapy in the treatment of acquired immunodeficiency syndrome-related Kaposis-sarcoma Semin. Oncol. 18 1991 53 57
125. A. Bottomley, and et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J. Clin. Oncol. 27 2009 2916 2923
126. K.R. Reddy, and et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C Hepatology 33 2001 433 438
127. A.M. Eggermont, and et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J. Clin. Oncol. 30 2012 3810 3818
128. D.W. Paty, and et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis. 2. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 1993 662 667
129. L.D. Jacobs, and et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG) Mult. Scler. 1 2015 118 135
130. U.T. Khan, and et al. PEGylated IFNbeta-1a in the treatment of multiple sclerosis Expert Opin. Biol. Ther. 15 2015 1077 1084
131. J.I. Gallin Interferon-gamma in the management of chronic granulomatous disease Rev. Infect. Dis. 13 1991 973 978
132. W.P. Sheridan, and et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy Lancet 339 1992 640 644
133. W.J. Gradishar, and et al. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia Blood 80 1992 2463 2470
134. A.M. Eggermont, and et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann. Surg. 224 1996 756 764
135. M. Franz, and et al. Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin Int. J. Cardiol. 195 2015 311 322
136. B. Carnemolla, and et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix Blood 99 2002 1659 1665